We can rapidly design and perform lead discovery campaigns in multiple therapeutic areas to identify compounds that reverse complex phenotypes and demonstrate confirmatory activity in orthogonal disease-specific validation assays.
Utilize our proprietary technology to develop “smart drug libraries” that maximize functional diversity and enable highly efficient parallel screening campaigns.
We conduct unbiased genetic suppressor screens at whole genome scale to provide biological insights around pathways and targets of interest to our partners across hundreds of disease models. Our molecular biologists and computational teams combine functional genomics and sophisticated AI methods in custom discovery programs for target identification and validation to suit the demands of each partner.
Recursion’s unique platform and portfolio of disease models uses AI, automation and cutting edge biology to quickly add value to our partners’ current pipelines.